Gardasil efficacious against HPV 16 infection

In a study of an extended follow up of 290 women naïve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.

The women enrolled in this study are a subset of the original Phase II HPV 16 proof-of-concept study published in 2002. Follow up ranged from 7.2 years to up to 9.5 years.

In a different study, in women ages 16 to 26 who were naïve to 14 common HPV types, GARDASIL reduced the number of abnormal Pap test results by 17 to 45 percent, depending on the abnormality, and reduced colposcopies by 20 percent, cervical biopsies by 22 percent and reduced surgery and other invasive treatments by 42 percent.

"We are encouraged by the extended efficacy data for the HPV 16 component of GARDASIL. Studies to examine the long-term efficacy of GARDASIL are underway," said Laura A. Koutsky, Ph.D., MSPH, University of Washington, School of Public Health. Dr. Koutsky and the University of Washington study site led this study extension. Merck & Co., Inc. is a co-author of the original data and the new analysis.

GARDASIL is currently indicated for use in girls and young women 9 through 26 years of age for the prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18.

HPV types 16 and 18 are responsible for approximately 70 percent of cervical cancer cases, and HPV types 6 and 11 are responsible for approximately 90 percent of genital warts and about 10 percent of low-grade cervical changes/lesions/dyplasias.

(Editor compiled and published Gardasil efficacious against HPV 16 infection at HealthNewsTrack on May 11, 2009 sourced from Merck & Co., Inc. - http://www.merck.com/)

Cervical cancer - recent articles and current news stories:

- HPV DNA testing for all women aged 29 years and above
- Cervical cancer virus HPV linked to oral cancer rise
- Breast cancer and cervical cancer rising in developing countries
- IUDs may lower cervical cancer risk
- Screening for cervical cancer too frequently

Cervical cancer article/news source:

Read more health articles from Merck & Co., Inc. and health articles from USA.

Cervical cancer - search related terms:

Cervical cancer, Cervical lesion, Gardasil, Genital wart, HPV, HPV infection, Human papillomavirus, Pap smear, Pap test,
Cervical cancer books,

Searched keywords: gardasil (9), hpv vaccine (5),

medical & health articles

Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.

Subscribe to Health News by Email

Current news
Studies of GARDASIL, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference

About Cervical cancer
Cervical cancer is a malignancy of the cervix, second most common cancer of women. It may present with vaginal bleeding but symptoms may be absent until the cancer is in advanced stages, which has made cervical cancer the focus of intense screening efforts utilizing the Pap smear. Most scientific studies point to human papillomavirus (HPV) infection as a necessary pre-requisite for development of cervical cancer.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
1.65